Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 12

Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo

Authors Samaka RM, Basha MA, Menesy D

Received 26 March 2019

Accepted for publication 22 May 2019

Published 28 June 2019 Volume 2019:12 Pages 469—480

DOI https://doi.org/10.2147/CCID.S210106

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Jeffrey Weinberg


Rehab M Samaka,1 Mohammed A Basha,2 Dina Menesy3

1Department of Pathology, Faculty of Medicine, Menoufia University, Shibīn al Kawm, Egypt; 2Department of Dermatology, Andrology and STDs, Faculty of Medicine, Menoufia University, Shibīn al Kawm, Egypt; 3General Organization for Teaching Hospitals and Institutes, Damanhour Medical National Institute, Damanhour, Egypt

Background: Vitiligo is an acquired autoimmune skin disorder. The often-visible lesions of vitiligo have a major impact on patients’ quality of life and the results of the treatment regimens on offer are unsatisfactory, so there is a need for new therapeutic regimens. Recent advances in vitiligo pathogenesis have led to recognition of the importance of the JAK–STAT pathway as an attractive therapeutic option.
Purpose: To evaluate role of JAK1 and STAT3 in vitiligo.
Methods: This prospective case–control study was carried out on 35 patients presenting with vitiligo and 20 apparently healthy age- and sex-matched volunteers. Skin biopsies from controls and cases were taken for histopathological and immunohistochemical JAK1 and STAT3 evaluation.
Results: Epidermal and dermal overexpression of STAT3 was noted in lesional skin compared to the other groups (P=0.02 and P<0.001, respectively). There was a positive correlation between dermal expression of JAK1 and dermal expression of STAT3 (r=0.52, P=0.004).
Conclusion: In conjunction, JAK1 and STAT3 might be involved in the pathogenesis of vitiligo. This could open the gate for the use of JAK1 and STAT3 inhibitors as new targeted therapy for vitiligo.

Keywords: JAK1, STAT3, vitiligo, immunohistochemical

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]